SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Conditions:   Type 2 Diabetes;   Type 1 Diabetes Interventions:   Drug: Empagliflozin 25 MG;   Other: Placebo Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials